Search results
Results from the WOW.Com Content Network
Prediction: CRISPR Therapeutics Stock Could Be a Millionaire-Maker. Prosper Junior Bakiny, The Motley Fool. August 4, 2024 at 6:22 AM. ... Its price in the U.S. is $2.2 million. Its total ...
Viking Therapeutics and CRISPR Therapeutics could be the best-performing biotechs through 2030, but they could also move in the opposite direction if things don't go their way. Invest accordingly.
CRISPR Therapeutics (NASDAQ: CRSP) isn't a stock that's wanting for reasons to invest. Per the company's presentation at the American Society of Hematology's (ASH) annual meeting on Dec. 9, the ...
The next two years may be a bit financially tight for CRISPR Therapeutics, which represents a risk for those who buy the stock now. As of the second quarter, it has about $484 million in cash ...
It won't be able to be profitable without hitting its targets for both of these figures.
For premium support please call: 800-290-4726 more ways to reach us
CRISPR Therapeutics has a $3.9 billion market cap at recent prices, but the stock is less expensive than it looks on the surface. With a big cash cushion and a lack of debt, its enterprise value ...
For premium support please call: 800-290-4726 more ways to reach us